Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaySearch Laboratories ABCHIX:RAYBS 95 3-Year EBITDA Growth Rate is 19.90% as of Jun. 2026, which is 6% above its 10-year median of 18.80. GuruFocus rates CHIX:RAYBS with a GF Score™ of 95/100 and a GF Value™ of kr187.45 (Fairly Valued). The stock has 2 warning signs investors should review. Among 526 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks better than 66.35% on this metric.
During the past 12 months, RaySearch Laboratories AB's average EBITDA Per Share Growth Rate was 12.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 19.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 27.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 11.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of RaySearch Laboratories AB was 111.20% per year. The lowest was -18.90% per year. And the median was 18.80% per year.
RaySearch Laboratories AB (CHIX:RAYBs) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
RaySearch Laboratories AB 3-Year EBITDA Growth Rate Related Terms
CHIX:RAYBS vs VEEV, BTSG, TEM: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, RaySearch Laboratories AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's 3-Year EBITDA Growth Rate falls into.
RaySearch Laboratories AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 19.90% mean?
RaySearch Laboratories AB (CHIX:RAYBS) has a 3-Year EBITDA Growth Rate of 19.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for RaySearch Laboratories AB and its competitors. This is near median its historical median of 18.80. According to the industry distribution chart, RaySearch Laboratories AB ranks #177 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 33.7%.
Is RaySearch Laboratories AB's 3-Year EBITDA Growth Rate too high?
RaySearch Laboratories AB's current 3-Year EBITDA Growth Rate of 19.90% is near median its 10-year median of 18.80. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. RaySearch Laboratories AB's value of 19.90% is 101% above this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #177 out of 526 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, RaySearch Laboratories AB has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #177 out of 526 companies for 3-Year EBITDA Growth Rate. This puts RaySearch Laboratories AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. RaySearch Laboratories AB's value of 19.90% is 101% above this benchmark. While the company's 10-year median is 18.80 vs. the industry median of 9.90, RaySearch Laboratories AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current 3-Year EBITDA Growth Rate of 19.90% is 101% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current 3-Year EBITDA Growth Rate is 19.90%, which is near median its own 10-year median of 18.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Fairly Valued. The stock's GF Value™ is kr187.45, compared to a current price of kr184.65 — trading 1.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 19.90%, which is near median its 10-year median of 18.80 and 101% above the Healthcare Providers & Services industry median of 9.90. RaySearch Laboratories AB's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current 3-Year EBITDA Growth Rate is 19.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be undervalued.
The current stock price of kr184.65 is trading 1.5% below its estimated GF Value™ of kr187.45.
GuruFocus considers RaySearch Laboratories AB to be Fairly Valued.
Key valuation signals for CHIX:RAYBS:
3-Year EBITDA Growth Rate: 19.90% (near median its 10-year median of 18.80)
GF Value™: kr187.45 vs. price of kr184.65 (1.5% below fair value)
Industry Position: 101% above the Healthcare Providers & Services median (#177 of 526)
No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
95GF Score
Get the complete analysis for CHIX:RAYBS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:RAYBS has been successfully added to your 
